ProCE Banner Activity

CAPTIVATE: Primary Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL

Slideset Download
Conference Coverage
In patients with previously untreated CLL/SLL, fixed-duration treatment of ibrutinib plus venetoclax resulted in deep and durable responses with high rates of treatment completion.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme